An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation
- PMID: 12692607
- DOI: 10.1038/sj.bmt.1703891
An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation
Abstract
The role of allogeneic bone marrow transplantation in lymphoma remains uncertain. We have analyzed 1185 allogeneic transplants for lymphoma reported to the EBMT registry between 1982 and 1998 and compared the results with those of 14687 autologous procedures performed over the same period. Patients receiving allogeneic transplants were subdivided according to histology: low-grade non-Hodgkin's lymphoma (NHL) 231 patients; intermediate-grade NHL 147 patients; high-grade NHL 255 patients; lymphoblastic NHL 314 patients; Burkitt's lymphoma 71 patients; and Hodgkin's disease 167 patients. These patients received allogeneic transplants as their first transplant procedure. Actuarial overall survival (OS) at 4 years from transplantation was: low-grade NHL 51.1%; intermediate-grade NHL 38.3%; high-grade NHL 41.2%; lymphoblastic lymphoma 42.0% years; Burkitt's lymphoma 37.1%; and Hodgkin's disease 24.7% years. These outcomes are relatively poor because of the high procedure-related mortality associated with these procedures, particularly in patients with Hodgkin's disease (51.7% actuarial procedure-related mortality at 4 years). Multivariate analysis showed that for all lymphomas apart from Hodgkin's disease, status at transplantation significantly affected outcome. A matched analysis was performed: for all categories of lymphoma, OS was better for autologous than for allogeneic transplantation. Relapse rate was better in the allogeneic group for low-, intermediate- and high-grade, and lymphoblastic NHL. It was equivalent for Burkitt's lymphoma and worse in the allogeneic group for Hodgkin's disease. Allogeneic transplantation appears to be superior to autologous procedures in terms of producing a lower relapse rate. The toxicity of allogeneic procedures must however be reduced before this translates into an improvement in OS.
Similar articles
-
Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.J Clin Oncol. 2003 Oct 15;21(20):3744-53. doi: 10.1200/JCO.2003.08.054. Epub 2003 Sep 8. J Clin Oncol. 2003. PMID: 12963703
-
Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR).Ann Hematol. 2005 Jul;84(7):462-73. doi: 10.1007/s00277-004-1003-3. Epub 2005 Feb 23. Ann Hematol. 2005. PMID: 15726362
-
Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada.Bone Marrow Transplant. 2000 Oct;26(8):859-64. doi: 10.1038/sj.bmt.1702625. Bone Marrow Transplant. 2000. PMID: 11081385
-
[Autologous stem cell transplantation in lymphomas and Hodgkin's disease].Acta Med Austriaca Suppl. 2000;52:25-9. Acta Med Austriaca Suppl. 2000. PMID: 11261274 Review. German.
-
Allogeneic stem cell transplantation for the non-Hodgkin's lymphomas and Hodgkin's disease.Cancer Treat Rev. 2000 Dec;26(6):411-27. doi: 10.1053/ctrv.2000.0179. Cancer Treat Rev. 2000. PMID: 11139372 Review.
Cited by
-
Allogeneic stem cell transplantation and CAR-T in B-cell Non-Hodgkin Lymphoma: a two-center experience and review of the literature.Ann Hematol. 2024 May;103(5):1717-1727. doi: 10.1007/s00277-024-05677-0. Epub 2024 Mar 2. Ann Hematol. 2024. PMID: 38429536 Review.
-
Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients.Blood Adv. 2019 Sep 24;3(18):2689-2695. doi: 10.1182/bloodadvances.2018026203. Blood Adv. 2019. PMID: 31511228 Free PMC article.
-
Hematopoietic stem cell transplantation for the management of follicular lymphoma.Stem Cells Cloning. 2010 May 3;3:69-80. doi: 10.2147/sccaa.s7014. Stem Cells Cloning. 2010. PMID: 24198512 Free PMC article. Review.
-
Management of relapsed diffuse large B-cell lymphoma.Curr Oncol Rep. 2008 Sep;10(5):393-403. doi: 10.1007/s11912-008-0061-4. Curr Oncol Rep. 2008. PMID: 18706267 Review.
-
Outcomes in relapsed Hodgkin's lymphoma treated with autologous and allogeneic hematopoietic cell transplantation at the Pontificia Universidad Católica de Chile.Rev Bras Hematol Hemoter. 2015 May-Jun;37(3):184-9. doi: 10.1016/j.bjhh.2015.03.011. Epub 2015 Apr 14. Rev Bras Hematol Hemoter. 2015. PMID: 26041421 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical